Law

In 2013, there was a slowdown in clinical trials due to clinical trial litigation. Afterward, India experienced an upward trend. Read more about the history of clinical trials and the risks in part I and part II of this series. There are several reasons behind the positive growth in clinical phase 1 and phase 2…

Although India has made adjustments to match global clinical trial regulation standards, the country still has some work to do. Several grey areas still need to be addressed. In some cases, regulatory authorities are the solution. Other issues require industry practices derived from trial and error. This unfortunately raises significant risk and liability questions. Clinical…

The emergence of initial coin offerings revolutionized public companies and fundraising. With very few SEC regulations, companies were allowed to raise millions of dollars that weren’t scrutinized by red tape. Companies who were able to sell their vision and coin to the public earned big. However, ICOs are now governed by regulatory bodies that provide…

The Indian pharmaceutical market is worthy of attention. It’s the third-largest globally by volume and 13th largest by value. The country is also the biggest producer of generic drugs, accounting for 20% of global exports in volume. In 2017, the Drug Controller General of India announced a new clinical trials policy. This policy provided greater…